Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Bio-Techne (TECH) over the last 17 years, with Q4 2025 value amounting to $14.0 million.

  • Bio-Techne's Share-based Compensation fell 509.93% to $14.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $41.6 million, marking a year-over-year increase of 372.43%. This contributed to the annual value of $40.8 million for FY2025, which is 733.66% up from last year.
  • As of Q4 2025, Bio-Techne's Share-based Compensation stood at $14.0 million, which was down 509.93% from $11.7 million recorded in Q3 2025.
  • In the past 5 years, Bio-Techne's Share-based Compensation registered a high of $16.7 million during Q4 2022, and its lowest value of -$2.1 million during Q2 2023.
  • Moreover, its 5-year median value for Share-based Compensation was $11.5 million (2025), whereas its average is $10.7 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first tumbled by 11651.62% in 2023, then soared by 43875.3% in 2024.
  • Over the past 5 years, Bio-Techne's Share-based Compensation (Quarter) stood at $14.0 million in 2021, then increased by 19.87% to $16.7 million in 2022, then decreased by 23.84% to $12.8 million in 2023, then rose by 15.33% to $14.7 million in 2024, then decreased by 5.1% to $14.0 million in 2025.
  • Its Share-based Compensation was $14.0 million in Q4 2025, compared to $11.7 million in Q3 2025 and $4.6 million in Q2 2025.